FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108524781> ?p ?o ?g. }

• W2108524781 abstract "Canagliflozin, an oral agent that inhibits sodium glucose co-transporter 2, improves glycemic control, body weight, and blood pressure and is generally well tolerated in patients with type 2 diabetes mellitus (T2DM). This study extends the scope of previous analyses by evaluating outcomes associated with the use of canagliflozin over a 6-month period in a real-world setting. This retrospective cohort study used data obtained from a large health plan database for patients (≥18 years) with a diagnosis of T2DM who filled at least one canagliflozin prescription between April 1, 2013 and October 30, 2013 (first 7 months canagliflozin was commercially available in the USA) and were continuously enrolled in the health plan for 6 months prior to (baseline) and 6 months following the first canagliflozin prescription claim (follow-up). Changes in glycemic control were evaluated, along with characteristics of enrolled patients and changes in treatment patterns. 4017 patients (mean age 56 years, 43 % female) met the study inclusion criteria. Of these, at the time of first canagliflozin claim, 21 % used canagliflozin concomitantly with three or more other antihyperglycemic agents (AHAs), 29 % with two other AHAs, 30 % with one other AHA, and 20 % without other AHAs. During follow-up, patients received 3.4 (average) canagliflozin prescription fills and a mean of 148 total days of supply; median adherence (interquartile range [IQR]) was 86 % (66–98 %) for patients with ≥2 fills. Among patients with available glycated hemoglobin (A1C) measurements at baseline and follow-up (n = 826, baseline A1C 8.59 %), mean A1C reduction was 0.81 % (P < 0.001). Mean A1C reduction during the follow-up period was greatest in patients with the highest baseline A1C levels. Of the patients who used canagliflozin concomitantly with other AHAs, 20 % were observed to discontinue one or more other AHAs during follow-up. The most commonly discontinued baseline AHAs were: glucagon-like peptide-1 receptor agonists (16 %), dipeptidyl peptidase-4 inhibitors (15 %), insulin (13 %), sulfonylureas (13 %), and metformin (11 %). This real-world study on canagliflozin use in a range of patients with T2DM demonstrated significant improvements in mean A1C from baseline following the first canagliflozin prescription. In patients concomitantly using one or more additional AHAs at baseline, there appears to be a trend toward lower other AHA use after canagliflozin initiation." @default.
• W2108524781 created "2016-06-24" @default.
• W2108524781 creator A5003514656 @default.
• W2108524781 creator A5017994555 @default.
• W2108524781 creator A5056463375 @default.
• W2108524781 creator A5078012819 @default.
• W2108524781 date "2015-11-02" @default.
• W2108524781 modified "2023-09-23" @default.
• W2108524781 title "Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis" @default.
• W2108524781 cites W1529223681 @default.
• W2108524781 cites W1924318177 @default.
• W2108524781 cites W2005469189 @default.
• W2108524781 cites W2007221722 @default.
• W2108524781 cites W2007329666 @default.
• W2108524781 cites W2047094893 @default.
• W2108524781 cites W2056523905 @default.
• W2108524781 cites W2063942209 @default.
• W2108524781 cites W2068171948 @default.
• W2108524781 cites W2069634424 @default.
• W2108524781 cites W2074989651 @default.
• W2108524781 cites W2090778088 @default.
• W2108524781 cites W2107288531 @default.
• W2108524781 cites W2123946565 @default.
• W2108524781 cites W2131135469 @default.
• W2108524781 cites W2135880911 @default.
• W2108524781 cites W2148382332 @default.
• W2108524781 cites W2156905679 @default.
• W2108524781 cites W2160088494 @default.
• W2108524781 cites W2162029846 @default.
• W2108524781 cites W2166823746 @default.
• W2108524781 cites W2168926920 @default.
• W2108524781 cites W2170243742 @default.
• W2108524781 cites W2171294019 @default.
• W2108524781 cites W2172193326 @default.
• W2108524781 cites W2302447233 @default.
• W2108524781 cites W2337365027 @default.
• W2108524781 cites W2337454357 @default.
• W2108524781 cites W2413163057 @default.
• W2108524781 cites W4240794548 @default.
• W2108524781 cites W4241911681 @default.
• W2108524781 doi "https://doi.org/10.1186/s12902-015-0064-8" @default.
• W2108524781 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4630836" @default.
• W2108524781 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26527413" @default.
• W2108524781 hasPublicationYear "2015" @default.
• W2108524781 type Work @default.
• W2108524781 sameAs 2108524781 @default.
• W2108524781 citedByCount "19" @default.
• W2108524781 countsByYear W21085247812016 @default.
• W2108524781 countsByYear W21085247812017 @default.
• W2108524781 countsByYear W21085247812018 @default.
• W2108524781 countsByYear W21085247812019 @default.
• W2108524781 countsByYear W21085247812020 @default.
• W2108524781 countsByYear W21085247812022 @default.
• W2108524781 countsByYear W21085247812023 @default.
• W2108524781 crossrefType "journal-article" @default.
• W2108524781 hasAuthorship W2108524781A5003514656 @default.
• W2108524781 hasAuthorship W2108524781A5017994555 @default.
• W2108524781 hasAuthorship W2108524781A5056463375 @default.
• W2108524781 hasAuthorship W2108524781A5078012819 @default.
• W2108524781 hasBestOaLocation W21085247811 @default.
• W2108524781 hasConcept C126322002 @default.
• W2108524781 hasConcept C134018914 @default.
• W2108524781 hasConcept C141071460 @default.
• W2108524781 hasConcept C167135981 @default.
• W2108524781 hasConcept C2426938 @default.
• W2108524781 hasConcept C2777180221 @default.
• W2108524781 hasConcept C2777451236 @default.
• W2108524781 hasConcept C2777538456 @default.
• W2108524781 hasConcept C2780473172 @default.
• W2108524781 hasConcept C2910068830 @default.
• W2108524781 hasConcept C555293320 @default.
• W2108524781 hasConcept C71924100 @default.
• W2108524781 hasConcept C98274493 @default.
• W2108524781 hasConceptScore W2108524781C126322002 @default.
• W2108524781 hasConceptScore W2108524781C134018914 @default.
• W2108524781 hasConceptScore W2108524781C141071460 @default.
• W2108524781 hasConceptScore W2108524781C167135981 @default.
• W2108524781 hasConceptScore W2108524781C2426938 @default.
• W2108524781 hasConceptScore W2108524781C2777180221 @default.
• W2108524781 hasConceptScore W2108524781C2777451236 @default.
• W2108524781 hasConceptScore W2108524781C2777538456 @default.
• W2108524781 hasConceptScore W2108524781C2780473172 @default.
• W2108524781 hasConceptScore W2108524781C2910068830 @default.
• W2108524781 hasConceptScore W2108524781C555293320 @default.
• W2108524781 hasConceptScore W2108524781C71924100 @default.
• W2108524781 hasConceptScore W2108524781C98274493 @default.
• W2108524781 hasIssue "1" @default.
• W2108524781 hasLocation W21085247811 @default.
• W2108524781 hasLocation W21085247812 @default.
• W2108524781 hasLocation W21085247813 @default.
• W2108524781 hasLocation W21085247814 @default.
• W2108524781 hasOpenAccess W2108524781 @default.
• W2108524781 hasPrimaryLocation W21085247811 @default.
• W2108524781 hasRelatedWork W1972766002 @default.
• W2108524781 hasRelatedWork W2010369654 @default.
• W2108524781 hasRelatedWork W2132751068 @default.
• W2108524781 hasRelatedWork W2318586790 @default.
• W2108524781 hasRelatedWork W2571643036 @default.
• W2108524781 hasRelatedWork W3010838544 @default.
• W2108524781 hasRelatedWork W3082240074 @default.

• next